Literature DB >> 21383051

Malaria immunoepidemiology in low transmission: correlation of infecting genotype and immune response to domains of Plasmodium falciparum merozoite surface protein 3.

Stephen J Jordan1, Ana L Oliveira, Jean N Hernandez, Robert A Oster, Debasish Chattopadhyay, OraLee H Branch, Julian C Rayner.   

Abstract

Malaria caused by Plasmodium falciparum is a major cause of global infant mortality, and no effective vaccine currently exists. Multiple potential vaccine targets have been identified, and immunoepidemiology studies have played a major part in assessing those candidates. When such studies are carried out in high-transmission settings, individuals are often superinfected with complex mixtures of genetically distinct P. falciparum types, making it impossible to directly correlate the genotype of the infecting antigen with the antibody response. In contrast, in regions of low transmission P. falciparum infections are often genetically simple, and direct comparison of infecting genotype and antigen-specific immune responses is possible. As a test of the utility of this approach, responses against several domains and allelic variants of the vaccine candidate P. falciparum merozoite surface protein 3 (PfMSP3) were tested in serum samples collected near Iquitos, Peru. Antibodies recognizing both the conserved C-terminal and the more variable N-terminal domain were identified, but anti-N-terminal responses were more prevalent, of higher titers, and primarily of cytophilic subclasses. Comparing antibody responses to different PfMSP3 variants with the PfMSP3 genotype present at the time of infection showed that anti-N-terminal responses were largely allele class specific, but there was some evidence for responses that cross-reacted across allele classes. Evidence for cross-reactive responses was much stronger when variants within one allele class were tested, which has implications for the rational development of genotype-transcending PfMSP3-based vaccines.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21383051      PMCID: PMC3088150          DOI: 10.1128/IAI.01332-10

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

1.  Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys.

Authors:  Hajime Hisaeda; Allan Saul; Joshua J Reece; Michael C Kennedy; Carole A Long; Louis H Miller; Anthony W Stowers
Journal:  J Infect Dis       Date:  2002-02-14       Impact factor: 5.226

2.  Toward the rational design of a malaria vaccine construct using the MSP3 family as an example: contribution of antigenicity studies in humans.

Authors:  Corine G Demanga; Lena-Juliette Daher; Eric Prieur; Catherine Blanc; Jean-Louis Pérignon; Hasnaa Bouharoun-Tayoun; Pierre Druilhe
Journal:  Infect Immun       Date:  2009-11-02       Impact factor: 3.441

3.  Plasmodium falciparum and Plasmodium vivax infections in the Peruvian Amazon: propagation of complex, multiple allele-type infections without super-infection.

Authors:  Patrick L Sutton; Victor Neyra; Jean N Hernandez; Oralee H Branch
Journal:  Am J Trop Med Hyg       Date:  2009-12       Impact factor: 2.345

4.  Allelic diversity and naturally acquired allele-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 in Kenya.

Authors:  Faith H A Osier; Gareth D Weedall; Federica Verra; Linda Murungi; Kevin K A Tetteh; Pete Bull; Bart W Faber; Ed Remarque; Alan Thomas; Kevin Marsh; David J Conway
Journal:  Infect Immun       Date:  2010-08-23       Impact factor: 3.441

5.  Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal.

Authors:  C Oeuvray; M Theisen; C Rogier; J F Trape; S Jepsen; P Druilhe
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

6.  Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design.

Authors:  Subhash Singh; Soe Soe; Juan-Pedro Mejia; Christian Roussilhon; Michael Theisen; Giampietro Corradin; Pierre Druilhe
Journal:  J Infect Dis       Date:  2004-07-27       Impact factor: 5.226

7.  Allele frequency-based and polymorphism-versus-divergence indices of balancing selection in a new filtered set of polymorphic genes in Plasmodium falciparum.

Authors:  Lynette Isabella Ochola; Kevin K A Tetteh; Lindsay B Stewart; Victor Riitho; Kevin Marsh; David J Conway
Journal:  Mol Biol Evol       Date:  2010-05-09       Impact factor: 16.240

8.  Malaria vaccines: where next?

Authors:  Anthony A Holder
Journal:  PLoS Pathog       Date:  2009-10-30       Impact factor: 6.823

9.  The Plasmodium falciparum merozoite surface protein-1 19 KD antibody response in the Peruvian Amazon predominantly targets the non-allele specific, shared sites of this antigen.

Authors:  Patrick L Sutton; Eva H Clark; Claudia Silva; OraLee H Branch
Journal:  Malar J       Date:  2010-01-04       Impact factor: 2.979

10.  Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children.

Authors:  Sodiomon B Sirima; Alfred B Tiono; Alphonse Ouédraogo; Amidou Diarra; André Lin Ouédraogo; Jean Baptiste Yaro; Espérance Ouédraogo; Adama Gansané; Edith C Bougouma; Amadou T Konaté; Youssouf Kaboré; Abdoulaye Traoré; Roma Chilengi; Chilengi Roma; Issiaka Soulama; Adrian J F Luty; Pierre Druilhe; Simon Cousens; Issa Nébié
Journal:  PLoS One       Date:  2009-10-26       Impact factor: 3.240

View more
  7 in total

1.  Socio-demographics and the development of malaria elimination strategies in the low transmission setting.

Authors:  Raul Chuquiyauri; Maribel Paredes; Pablo Peñataro; Sonia Torres; Silvia Marin; Alexander Tenorio; Kimberly C Brouwer; Shira Abeles; Alejandro Llanos-Cuentas; Robert H Gilman; Margaret Kosek; Joseph M Vinetz
Journal:  Acta Trop       Date:  2011-11-15       Impact factor: 3.112

2.  Antibodies directed against merozoite surface protein-6 are induced by natural exposure to Plasmodium falciparum in a low transmission environment.

Authors:  S J Jordan; A L Oliveira; A T Neal; J N Hernandez; O H Branch; J C Rayner
Journal:  Parasite Immunol       Date:  2011-07       Impact factor: 2.280

3.  Anti-Plasmodium falciparum invasion ligand antibodies in a low malaria transmission region, Loreto, Peru.

Authors:  Elizabeth Villasis; Mary Lopez-Perez; Katherine Torres; Dionicia Gamboa; Victor Neyra; Jorge Bendezu; Nancy Tricoche; Cheryl Lobo; Joseph M Vinetz; Sara Lustigman
Journal:  Malar J       Date:  2012-10-30       Impact factor: 2.979

4.  A full-length recombinant Plasmodium falciparum PfRH5 protein induces inhibitory antibodies that are effective across common PfRH5 genetic variants.

Authors:  Leyla Y Bustamante; S Josefin Bartholdson; Cecile Crosnier; Marta G Campos; Madushi Wanaguru; Chea Nguon; Dominic P Kwiatkowski; Gavin J Wright; Julian C Rayner
Journal:  Vaccine       Date:  2012-11-10       Impact factor: 3.641

5.  Genetic diversity of the merozoite surface protein-3 gene in Plasmodium falciparum populations in Thailand.

Authors:  Sittiporn Pattaradilokrat; Vorthon Sawaswong; Phumin Simpalipan; Morakot Kaewthamasorn; Napaporn Siripoon; Pongchai Harnyuttanakorn
Journal:  Malar J       Date:  2016-10-21       Impact factor: 2.979

6.  Natural antibody response to Plasmodium falciparum merozoite antigens MSP5, MSP9 and EBA175 is associated to clinical protection in the Brazilian Amazon.

Authors:  Márcia M Medeiros; Wesley L Fotoran; Rosimeire C dalla Martha; Tony H Katsuragawa; Luiz Hildebrando Pereira da Silva; Gerhard Wunderlich
Journal:  BMC Infect Dis       Date:  2013-12-28       Impact factor: 3.090

7.  Temporal changes in genetic diversity of msp-1, msp-2, and msp-3 in Plasmodium falciparum isolates from Grande Comore Island after introduction of ACT.

Authors:  Bo Huang; Fei Tuo; Yuan Liang; Wanting Wu; Guangchao Wu; Shiguang Huang; Qirun Zhong; Xin-Zhuan Su; Hongying Zhang; Mingqiang Li; Affane Bacar; Kamal Said Abdallah; Ahamada M S A Mliva; Qi Wang; Zhaoli Yang; Shaoqin Zheng; Qin Xu; Jianping Song; Changsheng Deng
Journal:  Malar J       Date:  2018-02-20       Impact factor: 2.979

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.